Roche’s Xofluza limits spread of flu virus, says new studyRoche’s new influenza drug Xofluza can dramatically prevent the spread of the virus when used as a preventive Share XRoche’s Xofluza limits spread of flu virus, says new studyhttps://pharmaphorum.com/news/roches-xofluza-limits-spread-of-flu-virus-says-new-study/
FDA reviewer backs Gilead’s Descovy for PrEP, but not in womenGilead Sciences’ Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, is heading into an FDA advisory Share XFDA reviewer backs Gilead’s Descovy for PrEP, but not in womenhttps://pharmaphorum.com/news/fda-reviewer-backs-gileads-descovy-for-prep-but-not-in-women/
ViiV files monthly HIV jab in EuropeViiV Healthcare has submitted its once-monthly two-drug injectable therapy for HIV to the EMA, setting up possible approval Share XViiV files monthly HIV jab in Europehttps://pharmaphorum.com/news/viiv-files-monthly-hiv-jab-in-europe/
ViiV’s first-in-class HIV drug on course for filings this yearViiV Healthcare has new data on its first-in-class HIV drug fostemsavir that back up its long-term effects, and Share XViiV’s first-in-class HIV drug on course for filings this yearhttps://pharmaphorum.com/news/viivs-first-in-class-hiv-drug-on-course-for-filings-this-year/
SMi’s Exclusive Interview with MedImmune Principal Scientist just releasedAn exclusive interview with Dr. Antonio DiGiandomenico, Principal Scientist, MedImmune has been released SMi Reports: An exclusive interview Share XSMi’s Exclusive Interview with MedImmune Principal Scientist just releasedhttps://pharmaphorum.com/partner-content/smis-exclusive-interview-with-medimmune-principal-scientist-just-released/
